

References



References

Afdhal NH, Levine R, Brown R, Freilich B, O'Brien M, and Brass C, (2008):

Colchicine versus PEG-interferon α -2b long term therapy: Results of the 4 year copilot trial.

J Hepatol 48: S4-S4.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, and Sulkowski MS, (2004):

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Gastroenterology 126: 1302-1311.

Afdhal NH and Geahigan T, (1999):

Supporting the patient with chronic hepatitis during treatment.

Humana Press,211 -232.

Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, and Del Ninno E, (2006):

Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.

Antivir Ther 11: 797-802.

Akazawa D, Date T, and Morikawa K, (2007):

CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection.

J Virol 81: 5036-5045.



References



Alejandro S, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ, and Hoofnagle JH, (2006):

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

Hepatitis C Support Project

Almer LJE, Cotler SJ, and Layden TJ, (2006):

Viral kinetics in the treatment of chronic hepatitis C.

J Viral Hepat 13(8): 499-504.

Alter MJ and Mast EE, (1994):

The epidemiology of viral hepatitis in the United States.

Gastroenterol Clin N AM 23: 437-55.

Andre P, Pradel KF, and Deforges S, (2002):

Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

J Virol 76: 69619-6928.

Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, and Zeuzem S, (2008):

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.

Aliment Pharmacol Ther 28: 397-404.

Ayalew T, Michelle AE, Soo YY, Chin YL, Ruben AM, Timothy GC, and Angela D, (2011):

Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.

Copyright 2011 by American Society of Hematology, Quoted from Blood 97(7): 1896.



References



Bacon BR, (2002):

Treatment of patients with hepatitis C and normal serum aminotransferase levels.

Hepatology 36: S179-184.

Barth H, Schafer C, and Adah MI, (2003):

Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulphate.

J Biol Chem 278: 41003-41012.

Bartosch B, Dubuisson J, and Cosset FL, (2003a):

Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes.

J Exp Med 197: 633-642.

Bartosch B, Vitelli A, and Granier C, (2003b):

Cell entry of hepatitis C virus requires a set of coreceptors that include CD81 and SR-B1 scavenger receptor.

J Biol Chem 278: 41624-41630.

Benhamou Y, Afdhal NH, Nelson DR, Shiffman ML, Halliman DG, and Heise J, (2009):

A phase III study of the safety and efficacy of viremagine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.

Hepatology 50: 717-726.

Berenguer M, (2005):

What determines the natural history of recurrent hepatitis C after liver transplantation?

J Hepatol 42: 448-456.



References

- =====
- Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, and Herrmann E, (2003a):
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Hepatology 37: 1359-1367.
- Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, and Zachoval R, (2003b):
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
Hepatology 37: 600-609.
- Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, and Gerlach T, (2006):
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Gastroenterology 130: 1086-1097.
- Bertaux C and Dragic T, (2006):
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.
J Virol 80: 4940-4948.
- Blanchard E, Belouzard S, and Goueslain L, (2006):
Hepatitis C virus entry depends on clathrin-mediated endocytosis.
J Virol 80: 6964-6972.
- Blight KJ, McKeating JA, and Rice CM, (2002):
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication.
J Virol 76: 13001-13014.



References



Bouchardeau F, Cantaloube JF, Chevaliez S, and Portal C, (2007):

Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA assay.

J Clin Microbiol 45(4): 1140-5.

Bowden DS and Berzsenyi MD, (2006):

Chronic hepatitis C virus infection: genotyping and its clinical role.

Future Microbiol 1: 103-12.

Bradrick SS, Walters RW, and Gromeier M, (2006):

The hepatitis C virus 3'-untranslated region or a poly (A) tract promote efficient translation subsequent to the initiation phase.

Nucleic Acids Res 34: 1293-1303.

Branch AD, Stump DD, and Gutierrez JA, (2005):

The hepatitis virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others.

Semin Liv Dis 25-105-117.

Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, and Negro F, (2005):

Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.

J Hepatol 42: 323-328.



References

- Bruchfeld A, Lindahl K, Schvarcz R, and Stahle L, (2002):
Dosage of ribavirin in patients with hepatitis C
should be based on renal function: a population
pharmacokinetic analysis.
Ther Drug Monit 24: 701-708.
- Bruchfeld A, Stahle L, Andersson J, and Schvarcz R, (2001):
Ribavirin treatment in dialysis patients with chronic
hepatitis C virus infection-2-a pilot study.
J Viral Hepat 8: 287-292.
- Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A,
and Sarrazin C, (2009):
Extended Treatment Duration in Chronic Hepatitis C
Genotype 1-Infected Slow Responders: Final Results
of the Success Study.
J Hepatol 50: S58-S58.
- Camma C, Giunta M, Andreone P, and Craxi A, (2001):
Interferon and prevention of hepatocellular carcinoma
in viral cirrhosis: an evidence-based approach.
J Hepatol 34: 593-602.
- Castera L, Vergniol J, Foucher J, and Le Bail B, (2005):
Prospective comparison of transient elastography,
Fibrotest, APRI, and liver biopsy for the assessment
of fibrosis in chronic hepatitis C.
Gastroenterology 128(2): 343-50.
- Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana
RJ, and Voigt M, (2005):
Peginterferon alfa-2a for hepatitis C after liver
transplantation: two randomized, controlled trials.
Hepatology 41: 289-298.

References

- Chao-Hung H, Chuan-Mo L, and Sheng-Nan L, (2006):
Anemia Associated With Antiviral Therapy in Chronic Hepatitis C: Incidence, Risk Factors, and Impact on Treatment Response.
Liver International 26(9): 1079-1086
- Chevaliez S, Alias BM, Brillet R, and Pawlotsky JM, (2007):
Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.
Hepatology 46(1): 22-31.
- Cocquerel L, Meunier JC, and Op de Beeck A, (2001):
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2.
J Gen Virol 82: 1629-1635.
- Codran A, Royer C, and Jaeck D, (2006):
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis.
J Gen Virol 87: 2583-2593.
- Colin C, Lanoir D, Touzet S, and Kraemer ML, (2001):
Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature.
J Viral Hepat 8(2): 87-95.
- Colucci G, Ferguson J, Harkleroad C, and Lee S, (2007):
Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study.
J Clin Microbiol 45(11): 3595-600.

References

=====
Cormier EG, Tsamis F, and Kajumo F, (2004):

CD81 is an entry coreceptor for hepatitis C virus.

Proc Natl Acad Sci [USA] 101: 7270-7274.

Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, and Reiser M, (2006):

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.

J Hepatol 44: 291-301.

Cornberg M, Huppe D, Wiegand J, Felten G, Wedemeyer H, and Manns MP, (2003):

Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3.

Z Gastroenterol 41: 517-522.

Cornberg M, Manns MP, and Wedemeyer H, (2010):

Hepatitis C Standard Care. In: "Hepatology: A Clinical Textbook; edited by Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H", 2nd edition, Flying Publisher, Düsseldorf, Germany, Part 3, Chapter 13, pp 171-195.

Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, and Skaug K, (2004):

Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.

Hepatology 40: 1260-1265.

References

=====

Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, and Skovlund E, (2008):

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.

Hepatology 47: 35-42.

Danta M, Brown D, and Bhagani S, (2007):

Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviors.

Aids 21(8): 983.

Date T, Kato T, and Miyamoto M, (2004):

Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells.

J Biol Chem 279: 22371-22376.

Davis GL, Alter MJ, El-Serag H, Poynard T, and Jennings LW, (2009):

Aging of the Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology.

Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, and Albrecht J, (2003):

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Hepatology 38: 645-652.

=====

References

de Ledinghen V, Trimoulet P, and Mannant PR, (2007):

Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years).

J Hepatol 46(1): 19.

Deterding K, Gruener N, Wiegand J, Buggisch P, Galle P, and Spengler U, (2009):

Early Versus Delayed Treatment of Acute Hepatitis C: The German Hep-Net Acute Hcv-III Study - a Randomized Controlled Trial.

J Hepatol 50: S380-S380.

DiBisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, and Wright EC, (2008):

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

N Engl J Med 359: 2429-2441.

Dumortier J, Scoazec JY, Chevallier P, and Boillot O, (2004):

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.

J Hepatol 40: 669-674.

Duvet S, Op de Beeck A, and Cocquerel L, (2002):

Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosyl-phosphoryl-dolichol deficient CHO mutant cell line.

Glycobiology 12: 95-101.

References

=====

Egger D, Wolk, and Gosert R, (2002):

Expression of hepatitis C virus proteins induces distinct membrane alterations including candidate viral replication complex.

J Virol 76: 5974-5984.

Einav S, Elazar M, and Danieli T, (2004):

A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication.

J Virol 78: 11288-11295.

Elazar M, Liu P, and Rice CM, (2004):

An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication.

J Virol 78: 11393-11400.

Evans MJ, von Hahn T, and Tscherne DM, (2007):

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.

Nature 446: 801-805.

Everson GT, (2004):

Treatment of chronic hepatitis C in patients with decompensated cirrhosis.

Rev Gastroenterol Disord 4(Suppl 1): S31-38.

Fabrizi F, Poordad FF, and Martin P, (2002):

Hepatitis C infection and the patient with end-stage renal disease.

Hepatology 36: 3-10.

=====

References

=====

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, and Brunner H, (2008):

PEG-IFN a-2a / RBV for 24 wks in HCV type 1 and 4 patients with rapid virological response.

Gastroenterology 135: 451-458.

Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, and Stauber R, (2009):

Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Types 1 and 4 Patients With Slow Virologic Response.

Gastroenterology.

Fissell RB, Bragg-Gresham JL, and Woods JD, (2004):

Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.

Kidney Int 65(6): 2335.

Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, and de la Mata M, (2003):

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

J Hepatol 39: 389-396.

Friebe P and Bartenschlager R, (2002):

Genetic analysis of sequences in the 3' nontranslated region of hepatitis C virus that are important for RNA replication.

J Virol 76: 5326-5338.

=====

References

- =====
- Friebe P, Boudet J, and Simorre JP, (2005):
Kissing-loop interaction in the 3' end of the hepatitis
C virus genome essential of RNA replication.
J Virol 79: 380-392.
- Friebe P, Lohmann V, and Krieger N, (2001):
Sequences in the 5' nontranslated region of hepatitis
C virus required for RNA replication.
J Virol 75: 12047-12057.
- Fried MW, (2002):
Side effects of therapy of hepatitis C and their management.
Hepatology 36: S237-244.
- Fried MW, Shiffman ML, Reddy KR, et al., (2002):
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis
C Virus Infection.
N Engl J Med 347: 975-982.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,
and Goncales JrFL, (2002):
Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection.
N Engl J Med 347: 975-982.
- Gardner JP, Durso RJ, and Arrigale RR, (2003):
L-SIGN (CD209L) is a liver-specific capture receptor
for hepatitis C virus.
Proc Nat. Acad Sci [USA] 100: 4498-4503.
- Gastaminza P, Cheng G, and Wieland S, (2008):
Cellular determinants of hepatitis C virus assembly,
maturation, degradation, and secretion.
J Virol 82: 2120-2129.

References

- Gebo KA, Herlong HF, and Torbenson MS, (2002):
Role of liver biopsy in management of chronic hepatitis C: a systematic review.
Hepatology 36(5 Suppl 1): S161.
- Gelderblom HC, Menting S, and Beld MG, (2006):
Clinical performance of the new rRoche COBAS TaqMan HCV Test and High Pure System for extraction, detection and quantitation of HCV RNA in plasma and serum.
Antivir Ther 11(1): 95-103.
- Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, and Ulsenheimer A, (2003):
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.
Gastroenterology 125: 80-88.
- Ghany MG, Strader DB, Thomas DL, and Seeff LB, (2009):
Diagnosis, management and treatment of hepatitis C: an update.
Hepatology 49: 1335-1374
- Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y, and Murphy B, (2007):
Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
J Hepatol 47: 51-59.
- Gitto S, Micco L, Conti F, Andreone P, Bernardi M, and (2008):
Alcohol and viral hepatitis: A mini-review.
Dig Liver Dis 24: 212-219.

References

=====

Goughoulte AM, Hourieux C, and Patient R, (2006):

Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly.

J Gen Virol 87: 855-860.

Gretton SN, Taylor AI, and McLauchlan J, (2005):

Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci.

J Gen Virol 86: 1415-1421.

Griffin SD, Beales LP, and Clarke DS, (2003):

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine.

FEBS Lett 535: 34-38.

Gronbaek H, Krarup HB, and Larsen RH, (2002):

Interferon alfa-2b alone or combined with recombinant granulocyte-macrophage colony-stimulating factor as treatment of chronic hepatitis C.

Scand J Gastroenterol 37: 840-44.

Grove J, Huby T, and Stamataki Z, (2007):

Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.

J Virol 81: 3162-3169.

Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, and Marcellin P, (2004):

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Ann Intern Med 140: 346-355.

=====

References

=====

Haley RW and Fischer RP, (2001):

Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status.

Medicine (Baltimore) 80(2): 134.

Haqshenas G, Mackenzie JM, and Dong X, (2007):

Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome.

J Gen Virol 88: 134-142.

Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, and Reddy RK, (2000):

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

N Engl J Med 343: 1673-1680.

Heck JA, Meng X, and Frick DN, (2009):

Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase.

Biochem Pharmacol 1173-1180.

Helle F and Dubuisson J, (2008):

Hepatitis C virus entry into host cells.

Cell Mol Life Sci 65: 100-112.

Heller TS, Saito J, and Auerbach T, (2005):

An in vitro model of hepatitis C virion production.

Proc Nat. Acad Sci [USA] 102: 2579-2583.

=====

References

=====

Hendricks DA, Friesenhahn M, Tanimoto L, and Goergen B, (2003):

Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis virus RNA. *J Clin Microbiol* 41(2): 651-6.

Heo TH, Chang JH, and Lee JW, (2004):

Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. *J Immunol* 173: 446-455.

Hofer H, Riedel WT, Janata O, Penner E, Holzmann H, and Munda SP, (2003):

Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. *Hepatology* 37: 60-64.

Hofmann WP, Dries V, Herrmann E, and Gartner B, (2005):

Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. *J Clin Virol* 32(4): 289-93.

Hraber P, Kuiken C, and Yusim K, (2007):

Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. *Hepatology* 46(6): 1713.

Hsu M, Zhang J, and Flint M, (2003):

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

=====

References



Proc Natl Acad Sci [USA] 100: 7271-7276.

Jacobson IM, Brown Jr RS, Freilich B, Afdhal N, Kwo PY, and Santoro J, (2007):

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *Hepatology* 46: 971-981.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, and Bodenheimer Jr HC, (2005):

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. *Am J Gastroenterol* 100: 2453-2462.

Jaekel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, and Zankel M, (2001):

Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 345: 1452-1457.

Janus PO, and Zobair MY, (2004):

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia.

Cliv Clin J Med 71(3): S17-S21.

Jennings TA, Chen Y, and Sikora D, (2008):

RNA unwinding activity of the hepatitis C virus NS3 helicase is modulated by the NS5B polymerase.

Biochemistry 47: 1126-1135.

Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, and Hadziyannis SJ, (2006):

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.



References

- Hepatology 43: 954-960.
- Jeong SH, Qiao M, and Nascimbeni M, (2004):
Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.
J Virol 78: 6995-7003.
- Jones CT, Murray CL, and Eastman DK, (2007):
Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus.
J Virol 81: 8374-8383.
- Jonsson JR, Purdie DM, Clouston AD, and Powell EE, (2008):
Recognition of genetic factors influencing the progression of hepatitis C: potential for personalized therapy.
Mol Diagn Ther 12(4): 209.
- Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, and Hakam SA, (2005):
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral.
- Kapadia SB, Barth H, and Baumert T, (2007):
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.
J Virol 81: 374-383.
- Kato J, Kato N, and Yoshida H, (2002):
Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo.
J Med Virol 66: 187-199.

References

Kato N, (2001):

Molecular virology of hepatitis C virus.

Acta Med Okayama 55: 133-159.

Kato T, Date T, and Miyamoto M, (2003):

Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon.

Gastroenterology 125: 1808-1817.

Kato T, Date T, and Miyamoto M, (2005):

Nonhepatic cell lines HeLa and 293 support efficient replication of hepatitis C virus genotype 2a subgenomic replicon.

J Virol 79: 592-596.

Kato T, Furusaka A, and Miyamoto M, (2001):

Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient.

J Med Virol 64: 334-339.

Kim YK, Kim CS, and Lee SH, (2002):

Domains I and II in the 5' nontranslated region of the HCV genome are required for RNA replication.

Biochem Biophys Res Commun 290: 105-112.

Konnick EQ, Erali M, Ashwood ER, and Hillyard DR, (2002):

Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay.

J Clin Microbiol 40(3): 768-73.

References

=====
Konnick EQ, Williams SM, Ashwood ER, and Hillyard DR, (2005):

Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays.

J Clin Microbiol 43(5): 2133-40.

Kou YH, Chou SM, and Wang YM, (2006):

Hepatitis C virus NS4A inhibits cap-dependent and the viral IRES-mediated translation through interacting with eukaryotic elongation factor 1A.

J Biomed Sci 13: 861-874.

Koutsoudakis G, Kaul A, and Steinmann E, (2006):

Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.

J Virol 80: 5308-5320.

Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I, and Scheurlen M, (2008):

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.

Gut 57: 531-536.

Krieger N, Lohmann V, and Bartenschlager R, (2001):

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

J Virol 75: 4614-4624.

Kupfer B, (2010):

HCV, Virology. In: "Hepatology: A Clinical Textbook; edited by Mauss S, Berg T, Rockstroh J,

References



Sarrazin C, Wedemeyer H", 2nd edition, Flying Publisher, Düsseldorf, Germany, Chapter 6, pp 61-82.

Lang C and Sarrazin C, (2010):
Diagnostic tests in acute and chronic Hepatitis C. In:
"Hepatology: A Clinical Textbook; edited by Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H",
2nd edition, Flying Publisher, Düsseldorf, Germany,
Part 3, Chapter 12, pp 159-170.

Lau JY, Tam RC, Liang TJ, and Hong Z, (2002):
Mechanism of action of ribavirin in the combination
treatment of chronic HCV infection.
Hepatology 35: 1002-1009.

Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, and
Hoofnagle JH, (1998):
Ten-year follow-up after interferon-alpha therapy for
chronic hepatitis C.
Hepatology 28: 1121-27.

Lauer GM and Walker BD, (2001):
Hepatitis C virus infection.
N Engl J Med 345(1): 41.

Lavillette D, Pécheur EI, and Donot P, (2007):
Characterization of fusion determinants points to the
involvement of three discrete regions of both E1 and
E2 glycoproteins in the membrane fusion process of
hepatitis C virus.
J Virol 81: 8752-8765.

Lavillette D, Tarr AW, and Voisset C, (2005):
Characterization of host-range and cell entry
properties of the major genotypes and subtypes of
hepatitis C virus.



References

- Hepatology 41: 265-274.
- Lee SC, Antony A, Lee N, and Leibow J, (2000):
Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.
J Clin Microbiol 38(11): 4171-9.
- Lim YS and Kim WR, (2008):
The global impact of hepatic fibrosis and end-stage liver disease.
Clin Liver Dis 12(4): 733.
- Lindenbach BD, Evans MJ, and Syder AJ, (2005):
Complete replication of hepatitis C virus in cell culture.
Science 309: 623-626.
- Lindenbach BD, Meuleman P, Ploss A, et al., (2006):
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro.
Proc Natl Acad Sci [USA] 103: 3805-3809.
- Lohmann V, Korner F, and Dobierzewska A, (2001):
Mutations in hepatitis C virus RNAs conferring cell culture adaptation.
J Virol 75: 1437-1449.
- Lozach PY, Jacob LH, and de Lavalette A, (2003):
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2.
J Biol Chem 278: 20358-20366.
- Luna RH, Khatib A, Sharma P, De Petris G, Williams JW, and Ortiz J, (2004):

References

- =====
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. *Transplantation* 77: 190-194.
- Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, and Sogari F, (2009):
Determinants of relapse after a short (12 week) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. *Hepatology* 49: 358-363.
- Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, and Carretta V, (2008):
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. *Hepatology* 47: 43-50.
- Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, and Persico M, (2005):
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
- Manns M, Lindsay KL, Gordon SC, Pockros PJ, Haeussinger D, and Hadziyiannis S, (2008):
Sustained virologic response after peginterferon alfa-2b and ribavirin treatment predicts long-term clearance of HCV at 5-year follow-up. *J Hepatol* 48: S300-S300.
- Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, and Klinker H, (2009):
Reduced Dose and Duration of Peginterferon Alfa-2b+Weight-Based Ribavirin in European and Asian

=====

References



Genotype 2 and 3 Chronic Hepatitis C Patients (Redd 2/3 Trial).

J Hepatol 50: S59-S59.

Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, and Goodman ZD, (2001):
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Lancet 358: 958-965.

Manns MP, Wedemeyer H, and Cornberg M, (2006):
Treating viral hepatitis C: efficacy, side effects, and complications.

Gut 55(9): 1350-9.

Marcellin P, Craxi A, Brandao-Mello CE, DiBisceglie AM, Andreone P, and Freilich B, (2008):
A 72-Week Treatment Duration with Peginterferon Alfa-2a (40kd) (Pegasys®) Plus Ribavirin (Copegus®) Has a Favorable Risk: Benefit Ratio in Non-Responders to Pegylated Interferon Alfa-2b (12kd) Plus Ribavirin: Findings of the Multinational Repeat Study.

Hepatology 48: 1147A-1147A.

McHutchison JG, (2004):
Understanding hepatitis C.

Am J Manag Care 10(2 Suppl): S21-9.

McHutchison JG, Dusheiko G, Shiffman ML, Torres RM, Sigal S, and Bourliere M, (2007):



References



Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles.

J Virol 80: 11571-11578.

Mende SJ, Bieck E, and Hugle T, (2001):

Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase.

J Biol Chem 276: 44052-44063.

Michelin BD, Muller Z, Stelzl E, and Marth E, (2007):

Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA.

J Clin Virol 38(2): 96-100.

Miyanari Y, Atsuzawa K, and Usuda N, (2007):

The lipid droplet is an important organelle for hepatitis C virus production.

Nat Cell Biol 9: 961-969.

Molina S, Castet V, and Wirth FC, (2007):

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

J Hepatol 46: 411-419.

Morishima C, Chung M, Ng KW, and Brambilla DJ, (2004):

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

J Clin Microbiol 42(1): 421-5.

Morota K, Fujinami R, Kinukawa H, and Machida T, (2009):

A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen.



References

- J Virol Methods 157(1): 8-14.
- Muir AJ and Provenzale D, (2002):
A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection.
J Clin Gastroenterol 34: 268-271.
- Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, and Goodkin RS, (2001):
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
N Engl J Med 344: 961-966.
- Nahmias Y, Casali M, and Barbe L, (2006):
Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes.
Hepatology 43: 257-265.
- Nakagawa M, Sakamoto N, and Tanabe Y, (2005):
Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins.
Gastroenterology 129: 1031-1041.
- Ndjomou J, Pybus OG, and Matz B, (2003):
Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon.
J Gen Virol 84: 2333-2341.
- Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, and Bejarano PA, (2004):
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.

References

- Transplantation 78: 1303-1307.
- Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, and Torres RM, (2009):
Efficacy and Safety Results of Albinterferon Alfa-2b in Combination with Ribavirin in Interferon-Alfa Treatment Naïve Patients with Genotype 2 or 3 Chronic Hepatitis C.
J Hepatol 50: S378-S378.
- Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, and Elewaut A, (2003):
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.
Hepatology 38: 1289-1296.
- Nolte FS, Fried MW, Shiffman ML, and Gonzalez FA, (2001):
Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests.
J Clin Microbiol 39(11): 4005-12.
- Otto GA, Lukavsky PJ, and Lancaster AM, (2002):
Ribosomal proteins mediate the hepatitis C virus IRES-HeLa 40S interaction.
RNA 8: 913-923.
- Pavlovic D, Neville DC, and Argaud O, (2003):
The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives.
Proc Nat. Acad Sci [USA] 100: 6104-6108.
- Pawlotsky JM, (2003):

References

- J Hepatol 43(3): 515.
- Perelson AS and Ribeiro RM, (2005):
Mutagenic effects of ribavirin in vivo.
J Hepatol 43: 553-555.
- Pietschmann T, Lohmann V, and Kaul A, (2002):
Persistent and transient replication of full-length hepatitis C virus genomes in cell culture.
J Virol 76: 4008-4021.
- Pischke S, Cornberg M, and Manns MP, (2008):
Hepatitis associated cryoglobulinemia.
Internist (Berl) 49: 297-304.
- Planas R, Balleste B, and Alvarez MA, (2004):
Natural history of decompensated hepatitis C virus-related cirrhosis: A study of 200 patients.
J Hepatol 40(5): 823.
- Ploss A, Evans MJ, and Gaysinskaya VA, (2009):
Human occluding is a hepatitis C virus entry factor required for infection of mouse cells.
Nature 457: 882-886.
- Pohlmann S, Zhang J, and Baribaud F, (2003):
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR.
J Virol 77: 4070-4080.
- Pomper GJ, Wu Y, and Snyder EL, (2003):
Risks of transfusion-transmitted infections: 2003.
Curr Opin Hematol 10(6): 412.
- Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, and George J, (2008):

References

- =====
Radosavljevic PM, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, and Gangl A, (2002):
Rapid suppression of hematopoiesis by standard or pegylated interferon alfa.
Gastroenterology 23: 141-51.
- Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, and Hamzeh FM, (2007):
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
Clin Gastroenterol Hepatol 5: 124-129.
- Ross RS, Viazov S, Sarr S, and Hoffmann S, (2002):
Quantitation of hepatitis C virus RNA by 3rd generation branched DNA-based signal amplification assay.
J Virol Methods 101(1-2):159-68.
- Roulot D, Czernichow S, and Le Clesiau H, (2008):
Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. J Hepatol 48(Suppl 2): S318.
- Roussel J, Pillez A, and Montpellier C, (2003):
Characterization of the expression of the hepatitis C virus F protein.
J Gen Virol 84: 1751-1759.
- Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, and Poordad F, (2009):
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.

References



Hepatology 50: 1719-1726.

Sabato MF, Shiffman ML, Langley MR, and Wilkinson DS, (2007):

Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus.

J Clin Microbiol 45(8): 2529-36.

Sakai A, Claire MS, and Faulk K, (2003):

The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences.

Proc Nat Acad Sci [USA] 100: 11646-11651.

Sangiovanni A, Prati GM, and Fasani P, (2006):

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.

Hepatology 43(6): 1303.

Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, and Mazzola M, (2005):

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

J Hepatol 42: 329-333.

Sarrazin C, (2002):

Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance.

J Clin Virol 25(Suppl 3): S23-9.



References



Sarrazin C, Gartner BC, Sizmann D, and Babel R, (2006):
Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.

J Clin Microbiol 44(3): 729-37.

Sarrazin C, Hendricks DA, Sedarati F, and Zeuzem S, (2001):
Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.

J Clin Microbiol 39(8): 2850-5.

Scarselli E, Ansuini H, and Cerino R, (2002):

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

EMBO J 21: 5017-5025.

Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, and Uebelhack R, (2005):

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

J Hepatol 42: 793-798.

Schiff E, Poordad E, Jacobson I, Flamm S, Bacon B, and Lawitz E, (2008):

Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness.

J Hepatol 48: S46-S46.

Schutten M, Peters D, Back NK, and Beld M, (2007):



References



Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

J Clin Microbiol 45(6): 1712-7.

Scott JD and Gretch DR, (2007):

Molecular diagnostics of hepatitis C virus infection: a systematic review.

JAMA 297(7): 724-32.

Shavinskaya A, Boulant S, and Penin F, (2007):

The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly.

J Biol Chem 282: 37158-37169.

Shiffman ML, DiBisceglie AM, Lindsay KL, Morishima C, Wright EC, and Everson GT, (2004):

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Gastroenterology 126: 1015-1023.

Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, and Stravitz RT, (2007a):

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.

Hepatology 46: 371-379.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, and Sola R, (2007b):

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

N Engl J Med 357: 124-134.



References



Simmonds P, (2001):

The origin and evolution of hepatitis viruses in humans.

J Gen Virol 82: 693-712.

Simmonds P, (2004):

Genetic diversity and evolution of hepatitis C virus-15 years on.

J Gen Virol 85: 3173-3188.

Simmonds P, Bukh J, Combet C, and Deleage G, (2005):

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Hepatology 42(4): 962-73.

Sizmann D, Boeck C, Boelter J, and Fischer D, (2007):

Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system.

J Clin Virol 39(4): 326-7.

Sjogren MH, Sjogren Jr R, Lyons MF, Ryan M, Santoro J, and Smith C, (2007):

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

Dig Dis Sci 52: 1540-1547.

Snoeck E, Wade JR, Duff F, Lamb M, and Jorga K, (2006):

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

Br J Clin Pharmacol 62: 699-709.



References

=====
Song Y, Friebe P, and Tzima E, (2006):

The hepatitis C virus RNA 3'-untranslated region strongly enhances translation directed by the internal ribosome entry site.

J Virol 80: 1579-11588.

Soza A, Everhart JE, Ghany MG, Doo E, Heller T, and Promrat K, (2002):

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

Hepatology 36: 1273-1279.

Spahn CM, Kieft JS, and Grassucci RA, (2001):

Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit.

Science 291: 1959-1962.

Sterling RK, Stravitz RT, and Luketic VA, (2004):

A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans.

Clin Gastroenterol Hepatol 2(6): 469.

Susser S, Dragan A, Zeuzem S, Sarrazin C, Lefkowitz JH, and Dancygier H, (2010):

Viral infection by Hepatotropic viruses. In: "Clinical Hepatology, Principles and Practice of Hepatobiliary Disease", 1st edition, Springer-Verlage, Berlin, Heidelberg, Vol 2, Section XII, Chapt 63, pp 671-822.

Sutton AJ, Hope VD, and Mathei C, (2008):

A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modeling study.

=====

References



J Viral Hepat 15(11): 809.

Svirtlih N, Jevtovic D, and Simonovic J, (2007):

Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C.

Hepatogastroenterology 54(80): 2324.

Swain MG, Lai MY, Shiffman ML, Cooksley WGE, Abergel A, and Lin A, (2007):

Durable sustained virological response after treatment with peginterferon alpha-2a (PEGASYS (R)) alone or in combination with ribavirin (COPEGUS (R)): 5-year follow-up and the criteria of a cure.

J Hepatol 46: S3-S3.

Tapias SJM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, and Barcena R, (2006):

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Gastroenterology 131: 451-460.

Terrault NA, (2003):

Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation.

Liver Transpl 9: S95-S100.

Terrault NA, Pawlotsky JM, McHutchison J, and Anderson F, (2005):

Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.

J Viral Hepatol 12(5): 465-72.



References



Thiel HJ, Collett MS, and Gould EA, (2005):
Family Flaviviridae, In: Fauquet CM, Mayo MA, Maniloff J et al., eds. Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press; pp 979-996.

Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, and Chisari FV, (2001):
Determinants of viral clearance and persistence during acute hepatitis C virus infection.
J Exp Med 194: 1395-1406.

Timpe JM, Stamataki Z, and Jennings A, (2007):
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.
Hepatology 47: 17-24.

Vahafi P, Marchadier E, Dussaix E, and Afonso RAM, (2009):
Hepatitis C virus genotyping: Comparison of the Abbott RealTime HCV Genotype II assay and NS5B sequencing.
Pathol Biol (Paris), epub.

Valli MB, Crema A, and Lanzilli G, (2007):
Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro.
J Med Virol 79: 1491-1499.

Valli MB, Seraino A, and Crema A, (2006):
Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact.



References

- chronic hepatitis C during interferon plus ribavirin combination therapy.
J Clin Microbiol 41(7): 3121-20.
- Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, and Zeuzem S, (2007):
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
Ann Intern Med 147: 677-684.
- von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, and Spengler U, (2008):
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Hepatology 48: 1404-1411.
- von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, and Heintges T, (2005):
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
Gastroenterology 129: 522-527.
- Wakita T, Pietschmann T, and Kato T, (2005):
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.
Nat Med 11: 791-796.
- Walewski JL, Keller TR, and Stump DD, (2001):
Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame.
RNA 7: 710-721.

References

=====

Wang H, Shen XT, and Ye R, (2005):

Roles of the polypyrimidine tract and 3' noncoding region of hepatitis C virus RNA in the internal ribosome entry site-mediated translation.

Arch Virol 150: 1085-1099.

Wasley A, Grytdal S, and Gallagher K, (2008):

Surveillance for acute viral hepatitis; United States, 2006.

MMWR Surveill Summ 57(2): 1.

Wasmuth JC, (2010):

Hepatitis C: Epidemiology, transmission and natural history. In: "Hepatology: A Clinical Textbook; edited by Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H", 2nd edition, Flying Publisher, Düsseldorf, Germany, Chapter 3, pp 19-29.

Watashi K, Ishii N, and Hijikata M, (2005):

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Mol Cell 19: 111-122.

Watson J, (2002):

Prospects for hepatitis C virus therapeutics: levovirin and viraclidine as improved derivatives of ribavirin.

Curr Opin Investig Drugs 3: 680-683.

Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, and Hoofnagle JH, (2002):

Impaired effector function of hepatitis C virus-specific CD8⁺ T cells in chronic hepatitis C virus infection.

J Immunol 169: 3447-3458.

=====

References



Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, and Schiefke I, (2009):
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
Vaccine 27: 5142-5151.

Weihofen A, Binns K, and Lemberg MK, (2002):
Identification of signal peptide peptidase, a presenelin-type aspartic protease.
Science 296: 2215-2218.

Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, and Frank H, (2001):
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C.
Gut 48: 378-383.

Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, and Berg T, (2006):
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.
Hepatology 43: 250-256.

Willems B, Hadziyannis SJ, Morgan TR, Diago M, Marcellin P, and Bernstein DE, (2007):
Increased SVR rate with 48 wks' treatment and higher RBV dose in HCV genotype 2/3 pts without a rapid virologic response (Rvr) treated with peginterferon alfa-2a (40KD) (Pegasys®) plus RBV (Copegus®).
Gastroenterology 132: A728-A728.

Witteveldt J, Evans MJ, and Bitzegeio J, (2009):



References



CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

J Gen Virol 90: 48-58.

Xu Z, Choi J, and Lu W, (2003):

Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum.

J Virol 77: 1578-1583.

Xu Z, Choi J, and Yen TS, (2001):

Synthesis of a novel hepatitis C virus protein by ribosomal frameshift.

EMBO J 20: 3840-3848.

Yang F, Robotham JM, and Nelson HB, (2008):

Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

J Virol 82: 5269-5278.

Yi M and Lemon SM, (2003):

3' Nontranslated RNA signals required for replication of hepatitis C virus RNA.

J Virol 77: 3557-3568.

Yi M, Villanueva RA, and Thomas DL, (2006):

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured hepatoma cells.

Proc Natl Acad Sci [USA] 103: 2310-2315.

You S and Rice CM, (2008):

3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U).

J Virol 82: 184-195.



References

=====

Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, and Collantes R, (2008):

A phase II dose finding study of darbepoetin alpha and ilgrastim for the management of anemia and neutropenia in chronic hepatitis C treatment.

J Viral Hepatol 15: 370-378.

Yu X, Qiao M, and Atanasov I, (2007):

Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles.

Virology 367: 126-134.

Zeisel MB, Koutsoudakis G, and Schnober EK, (2007):

Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.

Hepatology 46: 1722-1731.

Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, and Cianciara J, (2006):

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

J Hepatol 44: 97-103.

Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, and Prati D, (2004):

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

Gastroenterology 127: 1724-1732.

=====

References

- Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, and Sanchez-Tapias J, (2004):
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
J Hepatol 40: 993-999.
- Zeuzem S, Sulkowski M, Lawitz E, Rustgi V, Lurie Y, and Grigorescu M, (2009):
Efficacy and Safety of Albinterferon Alfa-2b in Combination with Ribavirin in Treatment-Naive, Chronic Hepatitis C Genotype 1 (Chc G1) Patients.
J Hepatol 50: S377-S377.
- Zhang J, Yamada O, and Yoshida H, (2002):
Autogenous translational inhibition of core protein: implication for switch from translation to RNA replication in hepatitis C virus.
Virology 293: 141-150.
- Zhang LQ, Randall G, and Higginbottom A, (2004):
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.
J Virol 78: 1448-1455.
- Zheng A, Yuan F, and Li Y, (2007):
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.
J Virol 81: 12465-12471.
- Zhong J, Gastaminza P, and Cheng G, (2005):
Robust hepatitis C virus infection in vitro.
Proc Natl Acad Sci [USA] 102: 9294-9299.
- Zignego AL and Craxi A, (2008):

References



Extrahepatic manifestations of hepatitis C virus infection.
Clin Liver Dis 12(3): 611.

Zignego AL, Ferri C, Pileri SA, Caini P, and Bianchi FB,
(2007):

Extrahepatic manifestations of Hepatitis C Virus
infection: a general overview and guidelines for a
clinical approach.

Dig Liver Dis 39: 2-17.

